Background: In almost 2 decades of naltrexone research for treating alcoholism, there have been 29 published randomized placebo-controlled trials of opioid antagonists, primarily naltrexone, for the treatment of alcohol dependence. The present review builds on prior systematic reviews while maximizing the number of included studies to date, for the purpose of resolving inconsistencies in naltrexone's reported efficacy across trials. Clinical trial results in this article are evaluated by the type of outcome measure used to determine naltrexone's treatment advantage, that is, measures related to reducing heavy drinking versus those related to increasing abstinence. Methods: We conducted a Medline search to identify double-blind studies from 1990 to the present (2006) that evaluated the use of an opiate antagonist for the treatment of alcohol dependence. There were 29 studies identified, representing 5997 alcohol-dependent patients, which met our study inclusion criteria for this review. Studies were evaluated in this review on 4 prespecified drinking outcomes-2 related to ''any drinking'' and 2 related to ''heavy or excessive drinking.'' Results: In the treatment of alcohol dependence, we found that 19 (70%) of 27 clinical trials that measured reductions in ''heavy or excessive drinking'' demonstrated an advantage for prescribing naltrexone over placebo, whereas only 9 (36%) of 25 clinical trials that measured abstinence or ''any drinking'' found an advantage for medication over placebo. Conclusion: The majority of double-blind clinical trials in the literature favored prescribing naltrexone for alcohol dependence to reduce heavy drinking. This finding is consistent with our understanding of naltrexone's mechanism of action of decreasing excessive drinking by reducing the reward associated with drinking alcohol. Thus, we conclude that outcome measures related to heavy or excessive drinking are most relevant to defining naltrexone's therapeutic effects. Factors influencing naltrexone response (treatment adherence and distinct patient subgroups) are also discussed.
(J Clin Psychopharmacol 2006; 26:610-625) N altrexone is an opioid receptor antagonist that reduces heavy drinking by diminishing the rewarding neurobiological effect of alcohol. The discovery that naltrexone can aid in treating alcoholism was the direct result of a systematic progression of studies from the laboratory to the clinic in an almost legendary path. 1 This line of inquiry ultimately led to the Food and Drug Administration (FDA) in 1994 approving naltrexone for the treatment of alcoholism in the United States. However, despite its FDA approval for treating alcoholism, naltrexone has not been widely prescribed in the United States for this purpose. 2 Recently, naltrexone has emerged at the forefront of alcoholism treatment research. The FDA approval in April 2006 of Vivitrol (Alkermes, Inc, Cambridge, Mass and Cephalon, Inc, Frazer, Pa) (an injectable long-acting form of naltrexone) for treating alcohol dependence, followed by the release of the results a month later from the national government-sponsored (National Institute on Alcohol Abuse and Alcoholism) COMBINE Study 3 showing that oral naltrexone given with a structured approach to medical management produced some of the best outcomes during 4 months of treatment, have ''reintroduced'' this relatively ''dated'' medication to the treatment community. In light of these latest developments, a thorough reevaluation of all of the existing literature on controlled naltrexone trials is warranted.
In almost 2 decades of naltrexone research for treating alcoholism, there have been 29 published, randomized, placebo-controlled trials of opioid antagonists, primarily naltrexone. Many of these studies, but not all, support the advantage of prescribing opiate antagonists as part of the treatment of alcohol dependence. There also have been a number of reviews that have favored naltrexone as a treatment of alcoholism, 4 -8 including 2 published meta-analyses that quantified the advantage that naltrexone has, compared with placebo (plus counseling), in reducing heavy drinking, albeit modest. 9, 10 Nonetheless, at least 1 large randomized, controlled naltrexone study has reported no advantage of naltrexone over placebo (eg, N = 627 11 ), and naltrexone's inconsistent results across some studies may have discouraged the medication's use in the treatment community.
The most frequent reason for treatment failure with naltrexone has been medication nonadherence. 12 -15 Some major naltrexone trials have been published that have demonstrated that the benefits of naltrexone are only seen in subjects who are reliable in taking their study medication every day. Although there may be no demonstrable advantage for naltrexone in the study sample as a whole, a clear advantage for naltrexone emerges when outcome data are based only on patients who received adequate exposure to the medication. 12 -14 In addition, recent studies suggest that specific patient subgroups may respond better to naltrexone than others. Subgroups of patients who appear to respond better to naltrexone include those with a specific genetic polymorphism in the m-opioid receptor gene 16 and those with enhanced opioidergic activity in response to alcohol ingestion. 17 A family history of alcoholism predicts a good naltrexone response, 18 -20 as does intense craving for alcohol. 20 As important as this topic is, however, constructing a profile for the optimal naltrexone responder will require further study.
One approach to a better understanding of naltrexone's efficacy is to consider outcome measures that are sensitive to the medication's proposed mechanism of action. As the field has gained a better understanding of how naltrexone behaves in the ''at-risk'' alcoholic brain, it has become clear that its most robust effect is reduction of excessive or heavy drinking, which may in some cases lead to an increase in the number of abstinent days. Heavy drinking has been defined as drinking 5 or more alcoholic drinks for men and 4 or more for women in a day. Reductions in heavy drinking with naltrexone likely results from naltrexone's action on reducing the pleasure or the ''high'' that many alcoholic patients report when drinking alcohol. 19, 21 Therefore, it could be predicted that naltrexone would more consistently provide a treatment advantage when treatment response is evaluated by measures related to reductions in heavy drinking rather than measures related to increased abstinence. However, many of the published naltrexone studies have either reported only 1 outcome measure or have evaluated several outcome measures without respect to naltrexone's purported action on reducing heavy drinking.
The recently published meta-analyses 9,10 have come closest to evaluating naltrexone's specific effects on reducing drinking by comparing effect sizes across various outcome measures. However, the stringent requirements for conducting meta-analyses inevitably result in excluding a number of clinically relevant studies. The present review builds on the available meta-analytic reviews by including, in one place, the largest number of published clinical trials on naltrexone (United States and internationally). Using a complementary perspective, this review purports to resolve some of the troubling inconsistencies in naltrexone's efficacy across the double-blind, placebo-controlled clinical trials by systematically evaluating results by the type of outcome measure used to determine naltrexone's treatment advantage (measures related to reducing heavy drinking versus those related to increasing abstinence). In addition, for those studies in which the majority of the study population was nonadherent, results for adherent subjects will be considered as the main results in this review whenever these results were reported. Resolving some of the apparent discrepancies in naltrexone's efficacy results across the growing number of clinical studies will expand our knowledge base of this treatment, better define a naltrexone responder/nonresponder, and provide more comfort for clinicians deciding whether to prescribe naltrexone for an alcohol disorder.
HISTORICAL AND CONTEMPORARY PERSPECTIVES ON NALTREXONE
By way of background, before the proposed evaluation of the existing naltrexone literature, this article will provide abbreviated historical and current perspectives on the use of opioid antagonists, primarily naltrexone, in the treatment of alcohol dependence. Naltrexone is the most commonly studied opioid antagonist for treating alcoholic patients. More information on the history and development of naltrexone is available. 1, 4, 5, 7 Path of Discovery: Naltrexone Treatment for Alcoholism Naltrexone, an antagonist at the m-, d-, and k-opioid receptors, was initially investigated more than 30 years ago for its utility in treating heroin and other opiate addictions and subsequently received FDA approval in 1984 for the treatment of opiate dependence. In the 1970s, preclinical data emerged demonstrating that opioid antagonists, such as naltrexone, blocked the ability of ethanol to increase dopamine release in the dopamine reward pathways leading from the ventral tegmental area to the nucleus accumbens. 22, 23 Other animal work showed that naloxone reduced alcohol preference in alcohol-dependent rats 24 and reduced drinking in rats bred for high levels of alcohol preference. 25 A seminal study by Altshuler and colleagues, 22 first presented in 1979 at the Committee on Problems of Drug Dependence, demonstrated that naltrexone blocked the selfadministration of alcohol in rhesus monkeys.
Persuaded by results emerging in the animal literature, O'Brien in 1983 initiated open dose ranging studies of naltrexone in alcoholic patients. Subsequently, he and Volpicelli initiated a placebo controlled clinical trial in chronic alcoholic patients at the Philadelphia Veterans Affairs Medical Center. 26, 27 The results of this 12-week study were consistent with preclinical findings. That is, naltrexone significantly reduced rates of relapse to heavy drinking, compared with placebo, with minimal side effects. These results were replicated in an independent study by O'Malley et al. 28 These 2 important studies provided the basis for the FDA approval of oral naltrexone in 1994 for the treatment of alcohol dependence in the United States. Naltrexone has also been approved for treatment of alcohol dependence in Australia, Canada, and a number of European countries.
Following naltrexone's FDA approval for alcohol use disorders, additional research has been conducted to clarify naltrexone's mechanism of action, 19, 21, 29 the effects of medication nonadherence on naltrexone outcomes, 12, 15 and profiling naltrexone responders and nonresponders. 16, 20 How Naltrexone Compares with Other FDA-Approved Pharmacotherapies for Alcoholism Naltrexone is the second (oral form) and fourth (injection lasting 30 days) of now 4 medications that have been approved in the United States specifically for treating alcohol dependence. Disulfiram was the first medication approved by the FDA for treating alcoholism in 1951, 30, 31 and the third medication, acamprosate, was approved by the FDA in 2004 for maintaining abstinence in the treatment of alcohol dependence. 32 -37 Although acamprosate and disulfiram are beyond the scope of this review, to provide a comparison to naltrexone, they are discussed briefly below.
The mechanism of action for disulfiram is to create a physiologically aversive state when combined with alcohol that includes flushing, nausea, and headache. These symptoms are sufficiently strong to induce some patients to immediately stop drinking alcohol. In this way, disulfiram does not directly address the pathophysiological changes associated with alcohol dependence. Evidence from clinical trials and private practice indicate that many patients skip medication doses so that they may consume alcohol without incident when they are experiencing an urge to drink alcohol. 30, 38 Disulfiram is used today successfully in treatment when patients can be supervised regularly taking their medication. 39 Still, today fewer than 250,000 disulfiram prescriptions are written in a year's time. 2 A comprehensive review of the disulfiram literature can be found elsewhere. 40 Acamprosate is a putative glutamate modulator that promotes abstinence by alleviating aversive symptoms related to protracted alcohol withdrawal. Like naltrexone, acamprosate effects neural pathways related to ethanol's effects on the brain. Meta-analyses suggest that naltrexone and acamprosate both have significant but modest effects on drinking outcomes. However, in the recently completed COMBINE study, acamprosate failed to demonstrate superiority over placebo with respect to increasing the number of days of abstinence. 3 However, these results are in contrast to a number of European clinical trials that have consistently supported the efficacy of acamprosate. 41 Naltrexone Today: Pharmacology, Safety, and Medication Adherence Both theoretical and empirical research have supported the ideas that alcohol dependence is a chronic disease and that biological vulnerabilities contribute to the pathogenesis of alcohol dependence. 42 -44 In addition, it has generally been thought that the identification of biological abnormalities in chronic diseases will allow more specificity in the pharmacological interventions used to remedy those conditions. One widely discussed area of biological vulnerabilities associated with alcohol dependence centers around neurotransmitter abnormalities. More than 2 decades of research has shown that dopamine is a principal neurotransmitter identified with the rewarding effects of substances of abuse. 45 -47 However, other neurotransmitters, such as endogenous opioids, also have been implicated in the selfadministration of alcohol and other substances, directly or indirectly through dopamine and other neurotransmitters involved in reward. 48 
Pharmacology
The most commonly studied opioid antagonist is naltrexone. When taken orally, naltrexone is quickly absorbed and undergoes first-pass metabolism in the cytosol system in the liver. 49 Naltrexone is then converted to several metabolites. The major metabolite of naltrexone is 6-bnaltrexol, which is also an opioid antagonist and by itself reduces alcohol drinking in a rat model. 50 Two other minor metabolites do not appear to significantly contribute to naltrexone's pharmacological activity or toxicity (2-hydroxy-3-methoxy-6-b-naltrexol and 2-hydroxy-3-methyl-naltrexone). The mean serum elimination half-life after chronic administration of a 50-mg daily dose is 9.7 hours for naltrexone and is 11.4 hours for 6-b-naltrexol. 51 In contrast, PET studies using C11 carfentanil show significant blocking of brain m receptors for more than 72 hours after a single 50-mg dose. 52 The suspected mechanism of action of naltrexone is a blunting of the reinforcing properties of alcohol, which are mediated in part through the endogenous opioid system. Naltrexone has high affinity for m receptors and good affinity for k-and d-opioid receptors, modulating the endogenous opioid system in the brain. Animal studies suggest that blockade of multiple opioid receptors weakens the pleasurable effects or ''high'' alcoholic patients report when drinking alcohol. 29 Several laboratory studies have demonstrated that naltrexone decreases the reinforcing or pleasurable effects of alcohol in social drinkers 53, 54 and alcoholic patients who sample alcohol. 19, 21, 29, 55 Safety Profile A decided advantage of naltrexone in the treatment of alcohol dependence is its safety profile. Historically, chronic drinkers often were denied medications (except for detoxification) due to safety concerns over the potential interaction of most medications with alcohol. However, naltrexone does not potentiate alcohol effects on motor skills or cognition or reduce seizure threshold; neither has naltrexone overdose produced any fatalities. In addition, naltrexone appears to have no significant abuse potential. That is, it has not been associated with pleasurable effects, nor physiological dependence, nor with tolerance to its opioid-blocking effects. 56, 57 Finally, in the decade before FDA approval for treating alcohol dependence, naltrexone had been given to more than 2000 detoxified intravenous-opioid abusers in numerous clinical trials. The frequency of side effects from naltrexone is relatively low (<15%). 58 Nausea and vomiting are the most common side effects reported with naltrexone. Headache, low energy, anxiety, depression, rashes, and decreased alertness are less common. 59 These side effects typically resolve spontaneously after a few doses, or by reducing the daily dosage. A few cases of dysphoria have been reported by patients with opioid addiction, 60, 61 and there are reports of increased dysphoria in normal volunteers given naltrexone. 62 These reports may be indicative of a mild opioid ''withdrawal-like'' reaction in some patients that occurs when naltrexone abruptly blocks opiate receptors that are in an activated condition, possibly due to stress or substance intake. Nonetheless, most studies have not found evidence of dysphoria or other mood changes with the recommended dose of naltrexone when treating patients dependent on opiates 63, 64 or alcohol. 26, 28 In naltrexone's package insert, there is a ''black-box'' warning of possible hepatocellular injury (when taken in approximately 7 times the recommended daily dose). It also states that naltrexone should not be given in cases of acute hepatitis or liver failure. This warning of hepatotoxic effects was derived from early studies, which prescribed dosages of up to 350 mg/d for obesity 65 -67 and dementia. 68 There are no reports of hepatotoxicity at the recommended daily dosage of 50 mg. In fact, liver enzyme levels in alcoholic patients typically are lowered with naltrexone treatment (relative to placebo), probably because of reduced alcohol intake while in treatment. Consequently, there appears to be a much greater risk of hepatotoxicity from chronic excessive alcohol drinking than from treatment with naltrexone at the recommended dosage. 69 DuPont Pharma conducted a large safety study of naltrexone (approximately 570 alcohol-dependent patients) and concluded that the medication was safe under a variety of circumstances. 58 Naltrexone also has been studied for use in several medical disorders other than alcohol and drug dependence, including obesity, 65 -67 bulimia, 70 dementia, 68 autism, 71 self-injurious behavior seen in autism, 72, 73 and mental retardation. 74 
Adherence Profile
Medication nonadherence is a universal phenomenon in chronic medical illnesses. Frequently nonadherence is related to medication side effects; however, this is only one of many possible reasons that patients might skip days of medication or stop taking their medication entirely. For example, there is typically a bias against taking medication for ''too long,'' or the cost of medication can impact medication adherence in clinical settings where the patient pays out of pocket (see more on this subject in Refs. 15,75 -78) .
In addition, historically, there has been a fundamental philosophical bias against taking medication for drinking problems. That is, medication nonadherence rates can be higher in alcoholic patients than in other patient populations, given the history of community attitudes toward alcohol treatment. In addition, unlike medications for most psychiatric conditions, opioid antagonists, such as naltrexone, neither alleviate distressful psychiatric symptoms nor inherently provide a sense of well-being or level of comfort. Rather, naltrexone's purported mechanism of action is to dampen the rewarding or euphoric feelings when drinking or thinking about drinking alcohol. Scientifically, the impact of blocking the ''high'' from alcohol can be enormous, given our knowledge about the brain, pleasurable reinforcement, memory, and repetitive behaviors. However, naltrexone's mechanism of action essentially translates clinically to a medication that may not provide immediate relief and seems to prevent the pleasurable feelings from alcohol. Adding naltrexone to counseling, however, can be powerful in highly motivated and medication-adherent patients. 12, 15 Nonetheless, getting patients to regularly take naltrexone over any length of time can be a problem in some settings and not taking naltrexone as prescribed is a major barrier to successful treatment response. That is, studies with high rates of medication nonadherence may inadvertently conclude that the medication is ineffective. The intent-totreat analyses, which can be comprised primarily of nonadherent patients in certain studies, may reveal no differences in drinking reductions between naltrexone-and placebo-treated subjects, unless a reanalysis is done to compare medication to placebo in patients who had good exposure to the medication/placebo (ie, were medication adherent, eg, Volpicelli et al 12 ) . Future studies of the impact of medication nonadherence and methods to enhance adherence are needed. Suggestions for enhancing adherence with taking naltrexone as prescribed can be found elsewhere. 15,75 -77 Now that extended release naltrexone is available, monthly injections are likely to result in better adherence. This type of delivery system conveniently bypasses the burden of daily decisions to take medications, particularly a medicine that will reduce the enjoyment derived from drinking. The several studies that have published results using one of several types of a long-acting injectable naltrexone have been included in this review.
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OPIOID ANTAGONISTS FOR ALCOHOLIC PATIENTS: CLINICAL TRIALS
In the past decade, there have been a number of well-controlled randomized clinical trials that have further tested the efficacy of opioid antagonists in treating alcohol dependence, with some of the studies failing to report any advantage for the medication over counseling alone. Inconsistent outcomes following FDA approval can be a major source of confusion and may unnecessarily discourage the use of an effective medication. On the other hand, the last decade has also provided us with an increased knowledge of how we think opiate antagonists work in treating alcoholism, allowing us to better target specific drinking behaviors (eg, reducing heavy drinking, which may or may not result in total abstinence from drinking). This knowledge has expanded the number and types of drinking measures being reported in more recent studies. Therefore, it is important to reevaluate the clinical trial evidence regarding opiate antagonists, primarily naltrexone, in the context of recently published studies, to fully understand the current status of naltrexone pharmacotherapy in the treatment of alcohol dependence.
Methods and Results
We conducted a Medline search to identify studies between 1990 and the present (2006) 95 by narrowing the search to human subjects and randomized controlled trials. The titles and abstracts for those 95 results were reviewed and limited to 27 appropriate trials. The reference lists of the 27 identified articles were also reviewed for relevant studies, and 2 additional trials were added based on that review for a total of 29 clinical trials.
To be included in this review, trials had to be published, randomized, double-blind, placebo-controlled, and include subject populations who were identified as having an alcohol disorder. We also arbitrarily decided that this review would not include any published results where the minimum sample size was fewer than 20 subjects. This was based on the supposition that a study with less than 10 subjects per treatment group is more similar to a case study than to a randomized controlled trial. Also, given that our aim for this review was to evaluate studies based on the type of outcome measures collected, we could only include studies that reported at least 1 of 4 possible outcome measures of drinking (defined below). When multiple publications reported results on the same subject group, only the primary publication was considered. A low rate of medication adherence (<50%) was not exclusionary, but when drinking outcomes for treatment-adherent patients were reported or easily derived from the publication, our review evaluated those outcomes. Following these few guidelines, we identified a total of 29 published studies, representing 5997 alcohol-dependent patients, which fit these criteria.
To obtain detailed drinking outcome data, all studies were searched for 4 prespecified well-known drinking outcome measures-2 related to ''any drinking'' and 2 related to ''excessive or heavy drinking.'' The majority of alcohol treatment studies have included some measure of abstinence or ''any drinking'' because these measures are often clinically relevant goals for treatment-seeking alcoholic patients. However, the effects of opiate antagonist pharmacotherapy on drinking are purported to be specific to reducing the reinforcement derived from consuming alcohol, which, in turn, predicts consuming less alcohol when drinking, but would not necessarily predict total abstinence. Little attempt has been made in clinical trials to tailor drinking outcome measures to purported mechanisms of specific pharmacotherapy, although many of the existing naltrexone trials included some measure of excessive or heavy drinking (eg, relapse-defined mainly as a return to heavy drinking, ie, increased volume). Very recent studies have included a measure that combines the frequency and intensity of drinking alcohol-days of heavy drinking. These latter 2 measures (ie, relapse and heavy drinking) are more specific to purported mechanisms of action of opiate antagonist pharmacotherapy. To this end, it was important in this review to evaluate the medications' effects on reducing excessive or heavy drinking, as well as their potential effects on any drinking. The 2 measures of ''any drinking'' we preselected to report for all studies are (1) the percentage or number of days drinking (16/29, 55%, studies reported this measure) and (2) the percentage of subjects who were abstinent or, if not provided, the percentage or number of days abstinent was reported (15/29, 52%, studies reported this measure). The 2 measures of ''excessive or heavy drinking'' are (1) the percentage of subjects who relapsed or the time (in days) to relapse (23/29, 79%, studies reported this measure) and (2) the percentage or number of days of heavy drinking (9/29, 31%, of the studies reported this measure). Relapse and heavy drinking were typically defined as: after starting treatment, drinking 5 or more drinks for men or 4 or more drinks for women in 1 day. A few of the studies expanded upon the minimal definition to include more than 1 heavy drinking day in a specified period. Two of the included studies reported primary outcome measures other than those described above. One study reported the defined outcome measures as probabilities (eg, the probability of heavy drinking). 82 Another study reported the percent reduction in heavy drinking. 79 Wherever possible, we included the studies' reported main outcome measure(s). Any major differences in definitions used in individual studies are documented (see footnotes to Table 2 ). However, other measures of drinking that may have been reported in the studies that could not be deemed a variation of the definitions we are using (eg, number of total drinks during treatment, liver enzyme levels) were not used as proxies for the predefined measures.
Although biomarkers, such as liver enzymes, were not used as primary outcome measures in this review, it should be noted that they have been put forth as possibly superior indicators of change in drinking behavior than the self-report measures evaluated in this review. 83 Liver enzyme levels, such as g-glutamyl transpeptidase, aspartate aminotransferase, and alanine aminotransferase, offer a clear advantage over self-report measures, in that they can be an objective indicator of safety and efficacy in alcohol treatment studies. On the other hand, using biomarkers in this context does introduce certain challenges and limitations that are not encountered with patients' self-reports. For example, (1) to detect a difference, the patient would need to have abnormal or elevated laboratory tests at treatment entry, and this is not the case for all alcohol-dependent patients entering treatment; (2) the patient's awareness that his or her drinking status may be verified by laboratory tests may influence attendance for such tests, as well as drinking behaviors; (3) biomarkers cannot be meaningfully evaluated too frequently as some period needs to pass in order for drinking behavior to affect them; (4) it is as yet unclear exactly how biomarkers, such as liver enzyme tests, can be quantified so that they are comparable across studies. 83 Liver enzyme levels are not typically viewed by the FDA as primary measures of efficacy for alcoholism clinical trials. It is for this reason, in conjunction with those limitations discussed above, that we chose not to include biomarkers in the outcome measures we systematically evaluated for the purposes of this review. However, biomarker results may illuminate otherwise confusing results in any given study included in this review. A notable example is the clinical trial results reported by Gastpar et al 84 (see summary tables). This study's primary drinking outcomes (self-report) after treatment with naltrexone indicated no advantage for naltrexone compared with placebo, but liver enzymes levels are significantly decreased in the naltrexone versus the placebo groups, suggesting that the naltrexone group likely had a substantial decrease in heavy or excessive drinking, compared with those treated with placebo. 84 There were 2 conclusion statements planned from our analysis of the 4 drinking outcome measures, regarding whether naltrexone/nalmefene had an advantage, or not, over placebo in treating alcohol dependence for (1) ''any drinking'' or (2) ''excessive drinking.'' One conclusion represents 2 measures of ''any drinking,'' and the second conclusion represents 2 measures of ''excessive drinking.'' If either of the outcome measures within a drinking category statistically favored naltrexone/nalmefene, then the conclusion per drinking category was stated: naltrexone or nalmefene > placebo, respectively. If neither of the 2 outcome measures within a drinking category statistically favored naltrexone/nalmefene, then the conclusion per drinking category was stated: naltrexone = placebo. It is worth noting that there were no instances in any of the studies we reviewed where placebo-treated patients had statistically more favorable drinking outcomes than those treated with naltrexone (ie, naltrexone < placebo).
Brief profiles of each of the 29 studies are presented in Table 1 .
3,11 -14,20,26 -28,79 -82,84 -100 The drinking outcomes and conclusions about the efficacy of the medications summarized in Table 1 are from detailed drinking outcome data for each of the 29 studies, which are reported in Table 2 .
Inspecting the last 2 columns in Table 1 reveals that the conclusions about the efficacy of opiate antagonists depend heavily on what type of drinking is measured (''any'' vs. ''excessive''). That is, naltrexone's efficacy was far less clear when the outcome focused on abstinence: only 9 studies (2517 subjects) of 25 studies that measured ''any'' drinking reported an advantage of medication over placebo in reducing drinking (36% of the studies that measured abstinence). However, with respect to ''excessive or heavy'' drinking, 19 (3950 subjects) of 27 studies that measured ''excessive'' drinking reported an advantage of medication over placebo in reducing excessive or heavy drinking (70% of the studies that measure heavy drinking).
Limitations
There are some limitations of our methods that bear noting. We chose not to conduct a meta-analysis. At this time, well-conducted meta-analyses of naltrexone treatment of alcohol dependence are available in the literature, and each of these supports the use of naltrexone clinically to reduce alcohol consumption in patients with alcohol problems, 9,10,101 although the effect sizes reported by these meta-analyses are modest. Our technique allowed us to simultaneously consider more trials than previous metaanalyses have been able to include. The most inclusive metaanalysis extant in the literature pools data from 9 trials (less than a third of the studies included in this review). 9 By including more trials, we have been able to present a more thorough summary of the literature and evaluate more types of outcome measures. The strength of this technique is that it has allowed us to be more comprehensive, but at the expense of employing more rigorous statistical methods, which might inspire stronger conclusions.
There are some key differences between studies included in this review. An important factor on which these studies vary is dosing and administration of the medication. Three of the studies included in this review used a depot, as opposed to oral, administration of naltrexone. 79 -81 As discussed earlier, long-acting injectable naltrexone may offer advantages over the orally taken pill form of the medication. There are also dosing inconsistencies among studies. Interestingly, a true dosing study was never conducted as part of the development of naltrexone. Variability in k-and d-receptor antagonism and intraindividual metabolism have led some investigators to consider dose to be important in understanding variability in outcomes. Although this is a reasonable hypothesis, only a few published studies prescribed more than 50 mg/d.
Some investigators have posited that the discrepancy between studies with positive and negative results could be explained in part by the goal of the concomitant psychosocial intervention that typically improved with adjunctive medication. 84 Evidence supports that naltrexone is effective in settings that use a coping approach (ie, an approach focused on discontinuing drinking), more so than settings that exclusively focus on the patient achieving complete abstinence. 84 Most of the studies in this review had relatively similar study populations. Typically, subjects were treatment seeking, community-referred patients who met diagnostic (DSM) 102 criteria for alcohol dependence, and no other substance dependence. However, there was 1 of the 29 studies with alcohol-dependent patient populations that is distinctively different from those included in the majority of the clinical trials, namely, patients with cocaine dependence. 87 This study found no advantage of 50 mg/d naltrexone for 12 weeks (over placebo) in reducing drinking for patients with both alcohol and cocaine dependence. This result is not surprising, given that alcohol-dependent patients with co-occurring cocaine dependence are more complicated at treatment entry, have higher attrition rates, and a poorer prognosis than patients with only alcohol dependence. 103, 104 In addition, most of the naltrexone studies reported in this review excluded patients who were taking or needed to take a psychotropic medication for a concurrent psychiatric illness. However, some of the naltrexone studies did include patients with a concurrent psychiatric diagnosis if they either did not need to take a medication or were stabilized for some time on a psychotropic medication. Although there is one controlled study that reported that naltrexone did not improve outcome more than placebo when added to an antidepressant (sertraline) in older adults with concurrent 106 
CONCLUSION
This review brings together in one place more than 2 dozen US and international clinical trials of opiate antagonists, primarily naltrexone, for the treatment of alcohol dependence, which were published since 1990. Essentially, we found that 19 of 27 clinical trials that measured reductions in ''heavy or excessive drinking'' demonstrated an advantage for medication over placebo (ie, 70% of relevant studies favored naltrexone), whereas only 9 of 25 clinical trials that measured abstinence or ''any drinking'' found an advantage for naltrexone over placebo (ie, 36% of relevant studies favored naltrexone). Thus, the majority of clinical trials in the literature favor prescribing naltrexone to reduce heavy drinking. This finding is consistent with our understanding of naltrexone's mechanism of action, and based on our review, we conclude that outcome measures related to heavy or excessive drinking are most relevant to defining naltrexone's therapeutic effects. These results underscore that the drinking outcome measures selected can make a difference in evaluating the efficacy of a pharmacotherapy in an alcohol-dependent population.
There are factors other than choice of outcome measure that have led some to characterize the literature on naltrexone as inconsistent and the effect size as ''modest.'' That is a fair characterization if one is comparing naltrexone for alcoholism to penicillin for pneumococcal pneumonia (before the appearance of resistant strains). Perhaps, a more appropriate comparison would be to major depression. Both depression and alcoholism are behavioral disorders that are strongly influenced by environmental factors and respond to psychotherapy to a significant degree. There are significant differences in the development of these 2 classes of agents that bear noting, however. For example, the trials of antidepressants that are published are mostly industry-supported trials and those trials selected for publication are likely heavily weighted toward positive trials. 107 Thus, effect sizes suggested based on the literature are potentially inflated. No one knows the proportion of trials that ''fail,'' but one estimate cited by a well-known depression researcher is 50%. 107 Naltrexone, in contrast, has a history of development outside the pharmaceutical industry, as described above, and we speculate that investigators in the field of alcohol treatment tend to publish everything. Another notable consideration is that the standard in addiction trials is to include a clinically proven behavioral intervention for both the placebo and active medication groups. In essence, these trials test the medication as adjunctive treatment and this has a consequence of producing seemingly high ''placebo'' response rates. This could have been the case in the large Veterans Affairs study 11 where the placebo success rate was much higher than the placebo rate, also in a Veterans Affairs population, of the first naltrexone/alcohol trial. 26 In contrast, depression trials are seldom done in combination with a behavioral intervention. In summary, issues related to research design may also contribute to the lack of robust naltrexone effects reported in the literature, as compared with effect sizes for other medications.
Methodological issues aside, there are known and potential barriers to naltrexone response that may account for inconsistent conclusions in the clinical trial data. Medication nonadherence and the heterogeneity of the patient population (eg, including alcoholic patients who use cocaine or other illegal substances) may have influenced efficacy outcomes in certain trials. We also acknowledge that there are probably endophenotypes of alcoholism, whereby some alcoholic patients will differentially respond to opioid-selective medications. Currently, our knowledge is limited by the comparatively sparse literature on alcoholic subtypes associated with response to alcohol in the laboratory, 17 response to naltrexone pretreatment on alcohol ''high, '' 21 and response to naltrexone according to family history 20 and genotype. 16 However, the handful of published studies examining predictors of naltrexone response/nonresponse suggests that this line of research may prove to be a fruitful means of selecting the best treatments for alcoholic patient populations.
Can We Define a Subgroup of Naltrexone Responders?
Once known or potential barriers to naltrexone response are addressed, there is a question of whether we will continue to find alcoholic patients who do not respond to naltrexone. Conversely, is there a subgroup of alcoholic patients who robustly respond to naltrexone in contrast to others with more modest responses?
The majority of studies that have examined the usefulness of naltrexone as a treatment of alcohol dependence have taken a general approach to selecting populations (via DSM diagnostic criteria) and have used a standard, double-blind, placebo-controlled study design that evaluates one medication against placebo. Recent negative studies, which have contributed to a dampening of enthusiasm for using these agents in treating alcohol dependence, may be explained by well-defined barriers to treatment, as discussed above. On the other hand, legitimate questions remain about whether there are identifiable characteristics of naltrexone responders and/or nonresponders related to biological vulnerabilities.
First, it is important to note that negative studies alone do not force the interpretation of alcoholic subgroups that poorly respond to naltrexone. In fact, the more damning interpretations of negative trials traditionally are that they were underpowered, have high rates of attrition, potentially underdosed patients, and/or included populations that were highly diversified. In addition, patients with suboptimal response are also likely to be poorly adherent to the treatment regimen. However, both human laboratory and clinical trial data have encouraged us to consider alcoholic subgroups that may be differentially responsive to alcohol and hence to naltrexone. Naltrexone is a medication that is specific for opiate receptors. If an alcoholic patient does not possess an endogenous opioid system that is sensitive to alcohol, naltrexone may have no effect. Indicators of opioidergic dysfunction could be specific genetic polymorphisms, 16 enhanced opioidergic activity in response to alcohol intake, 17 a family history of alcoholism, 18, 20, 21 and/or intense craving for alcohol. 20 Future work may identify alcoholic subgroups that will have the most optimal and/or poorest response to naltrexone pharmacotherapy.
